Results 111 to 120 of about 31,394 (214)

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

New England Journal of Medicine, 2009
B. Fellström, A. Jardine, R. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D. Chae, A. Chevaile, S. Cobbe, C. Grönhagen‐Riska, J. J. D. de Lima, R. Lins, G. Mayer, Alan W. McMahon, H. Parving, G. Remuzzi, O. Samuelsson, S. Sonkodi, D. Sci, G. Süleymanlar, D. Tsakiris, V. Tesar, V. Todorov, A. Więcek, R. Wüthrich, Mattis Gottlow, E. Johnsson, F. Zannad   +27 more
semanticscholar   +1 more source

Graft protective effects and donor-specific antibody suppression by CD4+CD25+Foxp3+ regulatory T cell induced by HMG-CoA reductase inhibitor rosuvastatin in a murine heart transplant model

Journal of Cardiothoracic Surgery
Background We previously demonstrated that the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statins) play an important role in the regulation of alloimmune responses.
Kazuhito Iguchi, Yasuto Yamamoto, Masateru Uchiyama, Hisanori Masaoka, Masahiro Nakamura, Hiroyuki Shizuka, Tomohiro Imazuru, Tomoki Shimokawa   +7 more
doaj   +1 more source

Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine.

PLoS ONE
Statins are considered as the first line drugs for the treatment of hyperlipidemia. Despite proven efficacy of rosuvastatin, inter-individual variations in plasma rosuvastatin levels have been documented in various studies which causes variable response ...
Mahjabeen Sharif, Kulsoom Farhat, Mudassar Noor, Ahsan Maqbool Ahmad, Dilshad Ahmed Khan, Raja Kamran Afzal, Muhammad Bilal Siddique   +6 more
doaj   +1 more source

Rosuvastatin Attenuates Pulmonary Damage in Rats with Cecal Ligation and Puncture-Induced Sepsis. [PDF]

J Clin Med
Yıldız Sİ, Saydam F, Topçu A, Tümkaya L, Kutlu EY, Uydu HA.   +5 more
europepmc   +1 more source

Cost-Utility Analysis of High-Intensity Statins; Atorvastatin 40 and 80 mg versus Rosuvastatin 20 mg from Egyptian Public Payer's Perspective: A Markov Model. [PDF]

Int J Prev Med
Ibrahim A, ElSherbiny D, Alhussaini MA, Masroja A, Anan I.   +4 more
europepmc   +1 more source

Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion. [PDF]

Cancer Immunol Immunother
Zhai Y, Yu Y, Bao R, Liu J, Fang J, Lu W, Zhang D, Guo H, Yao Y, Shi J.   +9 more
europepmc   +1 more source

Short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval: a target trial emulation. [PDF]

Eur J Clin Pharmacol
Chen X, Liu Y, Wei W, Xia X, Wu X, Lu X, Hu G, Lu S, Shen Y.   +8 more
europepmc   +1 more source

Development of Proteinuria in Patient With Solitary Kidney on Rosuvastatin. [PDF]

JACC Case Rep
Stouffer JA, Hansra BS.
europepmc   +1 more source

Real-world risk assessment of combined cilostazol-rosuvastatin: a retrospective cohort study using Korean electronic health records. [PDF]

Front Pharmacol
Shin WY, Jang HY, Lee K.
europepmc   +1 more source

Experimental beneficial effect of rosuvastatin on burn wound healing in a rat model. [PDF]

World J Exp Med
Marneri AG, Pavlidis ET, Stavrati KE, Kofinas A, Mouratidou C, Gkoutziotis I, Kotoulas SC, Marouda C, Psalla D, Ballas KD, Pavlidis TE.   +10 more
europepmc   +1 more source